White & Case Advises ADVANZ PHARMA on Sale to Nordic Capital

Press Release
1 min read

Global law firm White & Case LLP has advised ADVANZ PHARMA on its sale to Nordic Capital for an equity value of US$846 million. 

White & Case partner Mike Weir, who co-led the Firm's deal team, said: "We have worked with Graeme and the team at ADVANZ for a number of years and this latest transaction on which we've advised is an important development as they embark on a new stage for the business."

ADVANZ PHARMA is a specialty pharmaceutical company headquartered in London, with an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe and Australia, and an established global network of commercial partners throughout the rest of the world. With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe's major markets, ADVANZ PHARMA supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes.

Nordic Capital is a leading private equity investor with a focus on selected regions and sectors, including healthcare, technology & payments, financial services, and selectively, industrial and business services. 

Closing of the investment is subject to various regulatory approvals and the completion of the scheme of arrangement court process in Jersey.

The White & Case team in London which advised on the transaction was led by partners Mike Weir and Dominic Ross, with support from associates James Turner, Sonica Tolani and Josephine Levick. 

Press contact
For more information, please speak to your local media contact.